<DOC>
	<DOCNO>NCT00052884</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth plasma cell , either kill cell stop divide . Having peripheral stem cell transplant replace blood-forming cell destroy chemotherapy , allow high dose chemotherapy give plasma cell kill . Giving chemoprotective drug amifostine may protect kidney cell side effect chemotherapy . PURPOSE : This phase I trial study side effect best dose melphalan give together amifostine treat patient undergoing peripheral stem cell transplant primary systemic amyloidosis .</brief_summary>
	<brief_title>Amifostine Melphalan Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) high-dose melphalan administer amifostine patient primary systemic amyloidosis undergo autologous peripheral blood stem cell transplantation . - Determine toxicity high-dose melphalan administer MTD patient . - Determine response rate patient treat regimen . OUTLINE : This nonrandomized , multicenter , dose-escalation study melphalan . Patients receive filgrastim ( G-CSF ) subcutaneously daily peripheral blood stem cell ( PBSC ) collection complete . Apheresis begin day 5 G-CSF administration continue target number PBSCs collect . Within 6 week PBSC collection , patient receive amifostine IV 5 minute day -2 -1 high-dose melphalan IV 30-60 minute day -1 . Patients undergo autologous PBSC infusion day 0 . Cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 10 patient treat dose . Patients follow approximately 3 month follow transplantation , every 6 month 5 year . PROJECTED ACCRUAL : A total 3-46 patient accrue study within 2.3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm amyloidosis No secondary familial localize amyloidosis Presence monoclonal protein immunoelectrophoresis immunofixation serum urine No primary amyloidosis manifest carpal tunnel syndrome purpura Amyloid deposit plasmacytoma bone marrow vessel asymptomatic individual consider amyloid syndrome Amyloid syndrome include follow : Hepatomegaly Cardiomyopathy Nephrotic range proteinuria Peripheral autonomic neuropathy No multiple myeloma define 1 following : Presence lytic bone disease More 30 % bone marrow plasma cell PATIENT CHARACTERISTICS : Age 18 70 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Platelet count least 100,000/mm^3 Hepatic See Disease Characteristics Total direct bilirubin great 2.0 mg/dL Alkaline phosphatase great 4 time upper limit normal Renal See Disease Characteristics Creatinine le 3.0 mg/dL Cardiovascular See Disease Characteristics Ejection fraction least 45 % echocardiogram No New York Heart Association class III IV heart disease Systolic blood pressure â‰¥ 90 mmHg Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No malignancy within past 5 year except surgically treat carcinoma situ cervix , nonmelanoma skin cancer , indolent prostate cancer PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior interferon Chemotherapy At least 4 week since prior melphalan Lifetime total melphalan dose less 150 mg/m^2 ( base ideal body weight ) Endocrine therapy At least 4 week since prior dexamethasone Radiotherapy No prior radiotherapy amyloidosis Surgery Not specify Other No antihypertensive medication least 24 hour prior , , 1 hour amifostine administration No prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>